额外处女橄油 (EVOO) 改善了高脂血症患者的血管内皮功能和血液动力学参数:随机对照试验的后期分析
Christos Kourek1,2, Emmanouil Makaris3, Vassiliki Benetou2
1Department of Cardiology, 417 Army Share Fund Hospital of Athens (NIMTS), 11521 Athens, Greece.
Nutrients
|December 11, 2025
概括
额外处女橄油 (EVOO) 的消费改善了高脂血症患者的血管内皮功能和血液动力学参数. 高的EVOO在较低剂量时更有效,这表明它对心血管健康的好处.
科学领域:
- 心血管研究研究心血管研究
- 营养科学 营养科学
- 临床营养学 临床营养学
背景情况:
- 额外处女橄油 (EVOO) 具有抗氧化和抗炎性质.
- 在EVOO中的生物活性化合物可能会增强脂质代谢,将其定位为超脂血症的潜在干预措施.
- 以前的研究表明,EVOO对脂质代谢有好处.
研究的目的:
- 评估EVOO消费对高脂血症个体血管内皮功能和血液动力学参数的影响.
- 为了比较高和低EVOO在不同剂量的效果.
- 为了评估EVOO摄入后血压和心率的变化.
主要方法:
- 一个涉及70名参与者 (50名超脂血症患者,20名对照患者) 的后期分析.
- 每天摄入EVOO四周,高脂血症患者随机选择高 (低剂量) 或低 (高剂量) 的EVOO.
- 通过近红外光谱学 (NIRS) 评估血管内皮功能;作为次要结果测量了动脉血压和心率.
主要成果:
- 超脂血症患者表现出内皮功能显著改善,包括增加反和氧气消耗率.
- 摄入EVOO导致最大高血压时间和高血压恢复时间减少,表明血管功能得到改善.
- 观察到平静血压和心率显著下降;高醇EVOO在较低剂量时对静脉血压和再注射率表现出优异的影响.
结论:
- 在超脂血症患者中,EVOO的消耗对内皮功能和血液动力学参数产生积极影响.
- 高含量的EVOO显示出优越的血管益处,特别是在较低剂量时,与低含量的EVOO相比.
- 在高脂血症患者中,EVOO代表了管理血管健康的有前途的营养策略.
相关概念视频
Blood Studies for Cardiovascular System III: Serum Lipid Profile
534
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
534
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Hypertension IV: Drug Therapy and Lifestyle Modifications
575
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
575
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Hypertension and Regulation of Blood Pressure
3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424


